+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

G-Protein Coupled Receptors (GPCRs) - Global Strategic Business Report

  • PDF Icon

    Report

  • 359 Pages
  • February 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 1227782

Global G-Protein Coupled Receptors (GPCRs) Market to Reach $4.7 Billion by 2030

The global market for G-Protein Coupled Receptors (GPCRs) estimated at US$2.9 Billion in the year 2022, is projected to reach a revised size of US$4.7 Billion by 2030, growing at a CAGR of 6.1% over the analysis period 2022-2030. Cell Lines, one of the segments analyzed in the report, is projected to record 6% CAGR and reach US$1.8 Billion by the end of the analysis period. Growth in the Detection Kits segment is estimated at 6.7% CAGR for the next 8-year period.

The U.S. Market is Estimated at $1.1 Billion, While China is Forecast to Grow at 8.9% CAGR

The G-Protein Coupled Receptors (GPCRs) market in the U.S. is estimated at US$1.1 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$416.9 Million by the year 2030 trailing a CAGR of 8.9% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.3% and 6.1% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 5.8% CAGR.

Select Competitors (Total 52 Featured)

  • Merck KGaA
  • BD Biosciences
  • Enzo Life Sciences, Inc.
  • Lexicon Pharmaceuticals, Inc.
  • Molecular Devices LLC
  • Aragen Life Sciences Pvt. Ltd.
  • Axxam SpA
  • Abcam PLC
  • Eurofins Scientific SE
  • HD Biosciences Co., Ltd.
  • Addex Therapeutics
  • Multispan, Inc.
  • Creative Biolabs
  • Beacon Discovery
  • Distributed Bio

Economic Outlook

The global economic outlook is improving, and growth recovery, albeit on the lower side, is expected for this year and the next. The United States although witnessing slowing GDP growth in response to tight monetary and financial conditions, has nevertheless overcome the recession threat. Easing of headline inflation in Euro area is helping boost real incomes and is contributing to pick-up in economic activity. China is expected to see strong increases in GDP in the coming year as the pandemic threat recedes and the government sheds its zero-COVID policy. With optimistic GDP projections, India remains on-course to emerge into a US trillion economy by 2030, surpassing Japan and Germany.

The upturn, however, remains fragile and a number of interlocking challenges continue to run in parallel, such as continued uncertainty around the war in Ukraine; slower than expected decline in global headline inflation; continuation of food and fuel inflation as a persistent economic problem for most developing countries; and still high retail inflation and its impact on consumer confidence and spending. Countries and their governments are showing signs of weathering these challenges, which helps lift market sentiments. As governments continue to combat inflation to get it down to more economically conformable levels by raising interest rates, new job creation will slowdown and impact economic activity. Stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced.

Although corporate investments can likely be held back by inflation worries and weaker demand, rise of new technologies will reverse partially this prevailing investment sentiment. Rise of generative AI; applied AI; industrializing machine learning; next-generation software development; Web3; cloud and edge computing; quantum technologies; electrification and renewables and climate technologies beyond electrification and renewables, will open up the global investment landscape. The technologies hold the potential to drive sizeable incremental growth and value to global GDP in the coming years. The short-term is expected to be a mixed bag of challenges and opportunities for both consumers and investors alike. There is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

What`s New?

  • Special discussions on the global economic climate and market sentiment
  • Coverage on global competitiveness and key competitor percentage market shares
  • Market presence analysis across multiple geographies - Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to digital archives and trademarked research platform
  • Complimentary updates for one year
  • Access to curated YouTube video transcripts of market sentiments shared by CEOs, domain experts and market influencers via interviews, podcasts, press statements and event keynotes
Frequently Asked Questions about the G-Protein Coupled Receptors (GPCRs) Market

What is the estimated value of the G-Protein Coupled Receptors (GPCRs) Market?

The G-Protein Coupled Receptors (GPCRs) Market was estimated to be valued at $2.9 Billion in 2022.

What is the growth rate of the G-Protein Coupled Receptors (GPCRs) Market?

The growth rate of the G-Protein Coupled Receptors (GPCRs) Market is 6.2%, with an estimated value of $4.7 Billion by 2030.

What is the forecasted size of the G-Protein Coupled Receptors (GPCRs) Market?

The G-Protein Coupled Receptors (GPCRs) Market is estimated to be worth $4.7 Billion by 2030.

Who are the key companies in the G-Protein Coupled Receptors (GPCRs) Market?

Key companies in the G-Protein Coupled Receptors (GPCRs) Market include Merck KGaA, BD Biosciences, Enzo Life Sciences, Inc., Lexicon Pharmaceuticals, Inc., Molecular Devices LLC, Aragen Life Sciences Pvt. Ltd., Axxam SpA, Abcam PLC, Eurofins Scientific SE and HD Biosciences Co., Ltd..

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Impact of Covid-19 and a Looming Global Recession
  • Influencer Market Insights
  • World Market Trajectories
  • G-Protein Coupled Receptors (GPCRs) - Global Key Competitors Percentage Market Share in 2022 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • GPCR: An Introduction
  • Important Role of GPCRs in Drug Discovery
  • Popular Types of GPCRs of Therapeutic Interest
  • Classification of GPCRs
  • Orphan GPCRs: A Promising Area for Drug Discovery
  • GPCR Signaling Pathways
  • Physiological Roles Performed by GPCRs
  • Outlook
  • Geographic Market Analysis
  • Challenges
  • Competition
  • Recent Market Activity
  • World Brands
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Therapeutic Potential of GPCRs Gains Wide Recognition
  • Allosteric Modulators and Implication of Allostery in Drug Discovery
  • GPCRs Registered as Targets for Approved Drugs with EMBL-CHEMBL, IUPHAR, and The DrugBank
  • GPCRs Registered as Targets for Approved Drugs with EMBL-CHEMBL
  • GPCRs Registered as Targets for Approved Drugs with International Union of Basic and Clinical Pharmacology (IUPHAR)
  • GPCRs Registered as Targets for Approved Drugs with The DrugBank
  • FDA Approved GPCR Targeting Drugs (Excl. Diagnostic Agents) for the Period 2015-2019
  • Hurdles Faced…
  • Developments in Structural Biology and Receptor Pharmacology Offer Novel Opportunities to GPCR Drug Discovery
  • In Silico Approaches Underway for GPCR Drug Screening
  • Microfluidic Cell Technology Holds Potential
  • Pipeline GPCR Drug Candidates Widen Prospects
  • Select GPCR Small Molecule Drugs in Active Clinical Development
  • GPCR Ligands (Agonist) in Phase III Clinical Development
  • GPCR Ligands (Antagonist) in Phase III Clinical Development
  • New Indications to Aid Growth
  • CRISPR Holds Potential to Speed Up GPCR-based Drug Discovery
  • GPCR-targeted Drugs and Role in Cancer Treatment
  • Select FDA Approved Drugs and Antibodies against Various Cancer Types
  • Potential GPCR targets for Cancer Treatment
  • Anti GPCRs Drugs and Antibodies under Clinical Trials
  • Rising Incidence of Cancer to Drive Drives Opportunities
  • Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
  • Global Number of New Cancer Cases and Cancer-related Deaths by Cancer Site for 2018
  • GPCRs Evolve as Important targets for developing novel therapeutics for Neurodegerative Disorders
  • Number of Individuals Suffering from Alzheimer's in the US: 2020 and 2025
  • Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
  • GPCRs: An Important Target for Cardiovascular Drugs
  • Fatalities by Heart Conditions - Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others
  • GPCR Screening and Targeting Technologies
4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Recent Past, Current & Future Analysis for G-Protein Coupled Receptors (GPCRs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 2: World Historic Review for G-Protein Coupled Receptors (GPCRs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2021 and % CAGR
  • TABLE 3: World 15-Year Perspective for G-Protein Coupled Receptors (GPCRs) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2023 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for Cell Lines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 5: World Historic Review for Cell Lines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2021 and % CAGR
  • TABLE 6: World 15-Year Perspective for Cell Lines by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2023 & 2030
  • TABLE 7: World Recent Past, Current & Future Analysis for Detection Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 8: World Historic Review for Detection Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2021 and % CAGR
  • TABLE 9: World 15-Year Perspective for Detection Kits by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2023 & 2030
  • TABLE 10: World Recent Past, Current & Future Analysis for Cell Culture Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 11: World Historic Review for Cell Culture Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2021 and % CAGR
  • TABLE 12: World 15-Year Perspective for Cell Culture Reagents by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2023 & 2030
  • TABLE 13: World Recent Past, Current & Future Analysis for Ligands by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 14: World Historic Review for Ligands by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2021 and % CAGR
  • TABLE 15: World 15-Year Perspective for Ligands by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2023 & 2030
  • TABLE 16: World Recent Past, Current & Future Analysis for cAMP Functional Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 17: World Historic Review for cAMP Functional Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2021 and % CAGR
  • TABLE 18: World 15-Year Perspective for cAMP Functional Assays by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2023 & 2030
  • TABLE 19: World Recent Past, Current & Future Analysis for Calcium Functional Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 20: World Historic Review for Calcium Functional Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2021 and % CAGR
  • TABLE 21: World 15-Year Perspective for Calcium Functional Assays by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2023 & 2030
  • TABLE 22: World Recent Past, Current & Future Analysis for ß-Arrestin Functional Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 23: World Historic Review for ß-Arrestin Functional Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2021 and % CAGR
  • TABLE 24: World 15-Year Perspective for ß-Arrestin Functional Assays by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2023 & 2030
  • TABLE 25: World Recent Past, Current & Future Analysis for Radioligand Binding & GTPyS Functional Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 26: World Historic Review for Radioligand Binding & GTPyS Functional Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2021 and % CAGR
  • TABLE 27: World 15-Year Perspective for Radioligand Binding & GTPyS Functional Assays by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2023 & 2030
  • TABLE 28: World Recent Past, Current & Future Analysis for Internalization Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 29: World Historic Review for Internalization Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2021 and % CAGR
  • TABLE 30: World 15-Year Perspective for Internalization Assays by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2023 & 2030
  • TABLE 31: World Recent Past, Current & Future Analysis for Other Assay Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 32: World Historic Review for Other Assay Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2021 and % CAGR
  • TABLE 33: World 15-Year Perspective for Other Assay Types by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2023 & 2030
  • TABLE 34: World Recent Past, Current & Future Analysis for Cancer Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 35: World Historic Review for Cancer Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2021 and % CAGR
  • TABLE 36: World 15-Year Perspective for Cancer Research by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2023 & 2030
  • TABLE 37: World Recent Past, Current & Future Analysis for Metabolic Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 38: World Historic Review for Metabolic Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2021 and % CAGR
  • TABLE 39: World 15-Year Perspective for Metabolic Research by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2023 & 2030
  • TABLE 40: World Recent Past, Current & Future Analysis for Inflammation Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 41: World Historic Review for Inflammation Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2021 and % CAGR
  • TABLE 42: World 15-Year Perspective for Inflammation Research by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2023 & 2030
  • TABLE 43: World Recent Past, Current & Future Analysis for CNS Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 44: World Historic Review for CNS Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2021 and % CAGR
  • TABLE 45: World 15-Year Perspective for CNS Research by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2023 & 2030
  • TABLE 46: World Recent Past, Current & Future Analysis for Respiratory Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 47: World Historic Review for Respiratory Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2021 and % CAGR
  • TABLE 48: World 15-Year Perspective for Respiratory Research by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2023 & 2030
  • TABLE 49: World Recent Past, Current & Future Analysis for Cardiovascular Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 50: World Historic Review for Cardiovascular Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2021 and % CAGR
  • TABLE 51: World 15-Year Perspective for Cardiovascular Research by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2023 & 2030
  • TABLE 52: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 53: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2021 and % CAGR
  • TABLE 54: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2023 & 2030
  • TABLE 55: World G-Protein Coupled Receptors (GPCRs) Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
III. MARKET ANALYSIS
  • UNITED STATES
  • G-Protein Coupled Receptors (GPCRs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
  • CANADA
  • JAPAN
  • G-Protein Coupled Receptors (GPCRs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
  • CHINA
  • G-Protein Coupled Receptors (GPCRs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
  • EUROPE
  • G-Protein Coupled Receptors (GPCRs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
  • FRANCE
  • G-Protein Coupled Receptors (GPCRs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
  • GERMANY
  • G-Protein Coupled Receptors (GPCRs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
  • ITALY
  • UNITED KINGDOM
  • G-Protein Coupled Receptors (GPCRs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
  • REST OF EUROPE
  • ASIA-PACIFIC
  • G-Protein Coupled Receptors (GPCRs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
  • REST OF WORLD
IV. COMPETITION

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Merck KGaA
  • BD Biosciences
  • Enzo Life Sciences, Inc.
  • Lexicon Pharmaceuticals, Inc.
  • Molecular Devices LLC
  • Aragen Life Sciences Pvt. Ltd.
  • Axxam SpA
  • Abcam PLC
  • Eurofins Scientific SE
  • HD Biosciences Co., Ltd.
  • Addex Therapeutics
  • Multispan, Inc.
  • Creative Biolabs
  • Beacon Discovery
  • Distributed Bio